Checkpoint Kinase 2 Gene Mutation clinical trials at UCSF

1 research study open to eligible people

A CHEK2 gene mutation is a change that affects how cells fix DNA damage. UCSF is evaluating a PARP inhibitor combined with an oral decitabine-based drug in tumors that have BRCA1/2 or other DNA repair defects. UCSF is conducting an early phase study on safety and dose.

Showing trials for

  • Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

    open to eligible people ages 18 years and up

    This is a single center, phase I/Ib clinical trial evaluating the combination of the poly adenosine diphosphate-ribose polymerase (PARP) inhibitor olaparib with the DNA methyltransferase (DNMT) inhibitor ASTX727, which is an oral formulation of decitabine with cedazuridine (a cytidine deaminase inhibitor that allows for oral administration). The study population consists of adults with advanced/metastatic solid tumor malignancies with germline or somatic mutations in the HRR pathway (i.e., BReast CAncer gene 1 (BRCA1), BReast CAncer gene 2(BRCA2), Partner And Localizer of BRCA2 (PALB2), ATM, and/or Checkpoint kinase 2 (CHEK2) mutations).

    San Francisco, California

Our lead scientists for Checkpoint Kinase 2 Gene Mutation research studies include .

Last updated: